Series A · Biotech · Stockholm, Sweden · Founded 2020 · 4–10 employees
Tribune Therapeutics is a preclinical biopharmaceutical company developing novel medicines to treat fibrotic diseases by targeting CCN protein signaling pathways. Their lead candidate TRX-44 represents a breakthrough approach to treating multiple fibrotic conditions including idiopathic pulmonary fibrosis. The company raised €37 million in March 2025 led by LifeArc Ventures, with participation from notable investors including Novo Holdings and HealthCap. Founded in 2020 and based on groundbreaking research from Oslo University Hospital, Tribune is advancing toward clinical trials with their pan-anti-fibrotic platform.
No open roles listed right now.